SNDX: Dominant AML market share, advancing pivotal trials, and expanding pipeline in oncology and fibrosis
Strong commercial momentum continues with 85%+ AML market share and robust revenue growth. Multiple pivotal and innovative studies are advancing in AML, IPF, and GVHD, with key data readouts expected by year-end. Early-stage assets in EGFR-mutant lung cancer and myelofibrosis expand the pipeline.Ba…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.